According to KFF analysis of Centers for Medicare & Medicaid Services 2018-2022 Medicare Part D spending by drug increased from $57 Million to $5.7 Billion.[2] The June 13, 2024 article in Fierce Healthcare[3] on GLP-1 drugs noted that Blue Cross Blue Shield of Michigan will no longer cover these drugs starting in January 2025, and will be changing the prior authorization criteria starting in August 2024, for those members that are in large group fully insured commercial plans
Clin Nephrol 54(6):470477 Karaboyas A, Morgenstern H, Waechter S, Fleischer NL, Vanholder R, Jacobson SH, Sood MM, Schaubel DE, Inaba M, Pisoni RL, Robinson BM (2020) Low hemoglobin at hemodialysis initiation: an international study of anemia management and mortality in the early dialysis period
Baur A, Harrer T, Peukert M, et al
Association between cannabis use disorder and schizophrenia stronger in young males than in females
(2013) An emerging role of dipeptidyl peptidase 4 (DPP4) beyond glucose control: potential implications in cardiovascular disease
